A randomized, double-blind, double-dummy, parallel-group, multicenter study to evaluate and compare the effects of alendronate [alendronic acid] and raloxifene on bone mineral density in postmenopausal women with osteoporosis

Trial Profile

A randomized, double-blind, double-dummy, parallel-group, multicenter study to evaluate and compare the effects of alendronate [alendronic acid] and raloxifene on bone mineral density in postmenopausal women with osteoporosis

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Alendronic acid; Raloxifene
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Oct 2008 Planned number of patients changed from 400 to actual number 400 as reported by ClinicalTrials.gov
    • 01 Oct 2008 Actual end date added as 1 Jan 2003 as reported by ClinicalTrials.gov.
    • 13 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top